Grade downgraded from A+ to A (20 Jun 2026): Price ($195) has slipped below both EMA20 ($198.11) and EMA50 ($196.13), breaking the clean stack that justified the A+ at publication. Spot is only $1.10 above the published stop loss -- structure axis no longer passes.
Quest Diagnostics is the volume-driven leader of the US clinical-lab market, compounding revenue ~9% (Q1'26 +9.2% YoY) on rising testing volumes and a relentless acquisition cadence. Four straight earnings beats, a freshly raised FY26 EPS guide ($10.63–$10.83), low-0.6 beta and an undemanding ~18.5x forward PE make this a quality defensive name with an intact long-term trend. Price has pulled back from near its 52-week high and now trades below both EMA20 and EMA50, though still above EMA200 StockAnalysis· live.
Quest Diagnostics is one of the two national leaders of US clinical laboratory testing, processing billions of tests a year across routine bloodwork, advanced diagnostics, cancer genomics, and wellness panels. The model is fundamentally volume-driven: more requisitions flow through a fixed lab network, and incremental volume drops to the bottom line at high marginal economics. Revenue compounds through a dual engine — organic testing-volume growth plus a steady cadence of bolt-on hospital-lab and regional-lab acquisitions Quest IR· 2026.
The growth frontier is advanced diagnostics: in 2026 Quest deepened its oncology footprint with a multi-year clinical alliance built around its Haystack MRD circulating-tumor-DNA (ctDNA) test for minimal-residual-disease monitoring — positioning the company in the fast-growing liquid-biopsy market rather than just commodity bloodwork Yahoo Finance· 2026. The moat is scale (lowest cost per test), a national patient-service-center and phlebotomy footprint, and entrenched payer/health-system contracts — a structurally defensive business that grows steadily through cycles.
| Metric | Value | Signal |
|---|---|---|
| Revenue (TTM) | $11.28B | +9.2% YoY (Q1'26) |
| EBITDA (TTM) | $2.23B | 19.7% margin |
| Net Income (TTM) | $1.02B | Profitable |
| Gross Margin | 33.2% | Stable |
| Operating Margin | 14.2% | Healthy |
| Net Margin | 9.1% | Solid |
| ROE | 14.5% | Quality |
| EPS (TTM) | $9.05 | Growing |
| Cash | $0.39B | |
| Total Debt | $6.41B | Net Debt/EBITDA 2.7x |
| Fwd P/E | 18.2x | Reasonable |
| Analyst Target | $223.44 | +15% upside · Buy |
This is a high-quality defensive compounder, not a hyper-grower. High-single-digit revenue growth (~9% in Q1'26, ~7% FY26 guide) with a 14.5% ROE and ~20% EBITDA margins is exactly the profile that earns a market-multiple. At ~18.5x forward EPS against the raised $10.63–$10.83 guide, the valuation is undemanding — nowhere near nosebleed territory — and analysts still see ~15% upside to a $223 average target. The one honest caveat is leverage: net debt of ~$6.0B (2.7x EBITDA) is manageable for a stable cash generator but is a real line item — note the April 2026 senior-notes offering was a debt issuance (earmarked toward refinancing the 3.45% notes maturing June 2026), not new equity dilution.
No active equity ATM, no toxic convertibles, no stock-funded M&A, no aggressive boutique underwriters. The share count is shrinking, not growing.
The only recent SEC capital-markets event is the April 2026 prospectus supplement (424B5) under the company's existing S-3ASR automatic shelf (which technically permits debt and equity, though only debt has been drawn): a $500M offering of 5.000% senior NOTES due 2036, priced Apr 27 — pure debt. Per the filing, net proceeds are for general corporate purposes, which may include repaying the $500M 3.45% notes maturing June 1, 2026. This is debt issuance, not equity, and the underwriters were Goldman Sachs, J.P. Morgan and Mizuho — bulge-bracket banks, not the toxic-financing boutiques (Wainwright, Maxim, Dawson James) that signal death-spiral dilution PR Newswire· apr 2026. Diluted shares have fallen from ~127M to ~110.7M over recent years on consistent buybacks StockAnalysis Balance Sheet· jun 2026. SEC EDGAR (CIK 0001022079) shows no active equity shelf draw, no PIPE, no warrant overhang SEC EDGAR· jun 2026.
| RSI (14) | 50.9 |
| Price | $195.00 |
| EMA 20 | $198.11 |
| EMA 50 | $196.13 |
| EMA 200 | $189.82 |
| ATR (14) | $4.50 |
| Ext. vs EMA20 | -1.6% |
Update 20 Jun 2026: Structure has deteriorated since publication. Price ($195) has fallen below both EMA20 ($198.11) and EMA50 ($196.13), breaking the clean ordered stack that was in place at publication ($203.06). RSI has cooled to 50.9 (neutral). Spot sits only $1.10 above the published stop loss at $193.90 — dangerously tight. The broader trend remains intact (price still above EMA200) but the short-term structure no longer supports an A+ grade Finviz· live.
A defensive, recession-resistant cash generator with a low 0.59 beta. The principal risks are structural-industry (reimbursement) and balance-sheet (leverage), not existential.
DGX is a recession-resistant essential-services business: people get blood tested in good times and bad, which is why beta sits at 0.59. There is no dilution risk, no cash-burn risk, no going-concern question. The two genuine watch-items — Medicare/PAMA reimbursement pressure and the M&A-driven growth algorithm — are industry-structural and well-understood, not company-specific red flags. Leverage at 2.7x EBITDA is normal for a stable cash compounder, and the only recent capital-markets move was a debt refinancing, not equity issuance PR Newswire· apr 2026. This is about as low-drama as a momentum setup gets StockAnalysis· live.
Setup ON HOLD (20 Jun 2026): Price ($195) has fallen 3.4% below the published entry ($201.69) and sits only $1.10 above the stop ($193.90) — just 0.24 ATR of room. The EMA stack is broken (price < EMA20 < EMA50). This setup is not actionable at current levels. Do not enter a new position here; the published R/R assumes an entry that no longer aligns with the current structure. Wait for price to reclaim EMA50 ($196.13) and EMA20 ($198.11) before re-evaluating.
Original thesis (14 Jun): Buy a high-quality defensive compounder while it is breaking out, not when it is over-extended. DGX trades at ~18.5x forward earnings against a freshly raised FY26 guide ($10.63–$10.83), has beaten estimates four quarters running. A buy-limit at $201.69 with a stop below the EMA50 cluster gives a 2.0R move to a 52-week-high breakout (TP1) and 3.2R to a new-high extension above the $223 analyst target (TP2). R/R = (217.27 - 201.69) / (201.69 - 193.90) = 2.0 at TP1.
Status (20 Jun): The clean EMA stack that supported this thesis has broken. Price has fallen below both EMA20 and EMA50, and the buy-limit entry at $201.69 was never triggered at the current price of $195. The fundamental thesis (defensive compounder, 4/4 beats, raised guide) remains intact, but the technical setup requires reclamation of structure before re-entry. This is a WAIT, not a BUY.
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data sourced from DailyTickers Gateway, Yahoo Finance, StockAnalysis.com, MarketBeat, and SEC EDGAR. Accuracy is not guaranteed.